Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

188.46 +2.84 (+1.53%)
Streaming Delayed Price Updated: 10:43 AM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
81 82 Next >
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet. 
Via MarketBeat
Topics Bonds
AbbVie's Big Buy Of ImmunoGen Opens Doors For Potential Investment Gains
AbbVie's $10.1 billion acquisition of ImmunoGen, with its promising ovarian cancer drug, Elahere, signals a strategic move in the competitive cancer drug market. Investors anticipate market reactions,... 
Via Talk Markets
2 Dividend Stocks to Buy and Hold Forever
These stocks offer much more than reliable dividends. 
Via The Motley Fool
Analyst Ratings for AbbVie
Via Benzinga
Health Care Company AbbVie Announces Acquisition of Immunogen
Via Benzinga
AbbVie Should Consider a Dividend Cut -- Here's Why
Dividend Kings with above-average yields have been badly underperforming the broader markets. 
Via The Motley Fool
5 S&P 500 Stocks That Pay a Generous Dividend
Investors are pocketing dividend yields between 4% and 9% with these stocks. 
Via The Motley Fool
Topics Stocks
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
These biotechs targeting multiple neurodegenerative diseases
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market. 
Via MarketBeat
Medtronic Stock: Bull vs. Bear
The medical device maker's shares have gained a little more than 1% so far this year. 
Via The Motley Fool
How Is The Market Feeling About AbbVie?
Via Benzinga
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion. 
Via Talk Markets
Why Abbvie Stock Popped Today
The company announces a major deal worth over $10 billion. 
Via The Motley Fool
ImmunoGen's Flagship Cancer Therapy Draws AbbVie's Attention With $10.1B Deal
AbbVie Inc (NYSE: ABBV) has agreed to acquire ImmunoGen Inc (NASDAQ: IMGN) and its flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC)... 
Via Benzinga
Why Is ImmunoGen (IMGN) Stock Up 81% Today?
ImmunoGen stock is taking off on news that AbbVie is acquiring all outstanding shares of IMGN in a $10.1 billion acquisition deal. 
Via InvestorPlace
AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal
IMGN stock soared after AbbVie agreed to buy ImmunoGen for $10.1 billion, offering a rich premium for the maker of cancer drug Elahere. 
Via Investor's Business Daily
Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today’s Economy
These are the best blue-chip stocks for investors to consider among a group of already strong equities available in the market. 
Via InvestorPlace
AbbVie's Lung Cancer Study Shows Encouraging Clinical Benefits In Subtype Of Patients
AbbVie Inc (NYSE: ABBV) announced topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal... 
Via Benzinga
These are the top sectors for blue chip growth in 2024
The sector results will be mixed in 2024 but the Health Care, Communications and Technology sectors (and some of their stocks) will post robust gains. 
Via MarketBeat
Topics Economy Intellectual Property
J&J, Gilead, BMS: A look at undervalued dividend payers
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown 
Via MarketBeat
Biotech And Healthcare Portfolio Playbook For December 2023/24
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
3 Rising Stars: Invest Now in Tomorrow’s Trillion-Dollar Companies
If you are an investor looking for secret rising stars, explore these three that can reach trillion dollar status. 
Via InvestorPlace
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
There's no time like the present to buy these stocks. 
Via The Motley Fool
Could AbbVie Stock Help You Become a Millionaire?
Buying the stock at a cheap price today could help you achieve some great long-term returns. 
Via The Motley Fool
3 "Boring" Stocks That Could Make You Rich
Boring could be beautiful with these stocks. 
Via The Motley Fool
Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now
Investors have favored an exciting billion-dollar opportunity at Eli Lilly. 
Via The Motley Fool
Dual Powerhouses: 7 Dividend Stocks Marrying High Yield With High Growth
Although you can’t usually have your cake and eat it too, these compelling high-yield dividend growth stocks may prove otherwise. 
Via InvestorPlace
7 High-Yield Blue Chips Suitable for Any Retiree
Here are seven high-yield blue-chip stocks to help you meet your retirement goals no matter where you are on your investment journey. 
Via InvestorPlace
Topics Retirement
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.